Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma -- CA209-010
Immune checkpoint inhibitors targeting the PD-1 pathway have transformed the management of many advanced malignancies, including clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of PD-1 response remain incompletely elucidated. Here, we analyzed 592 tumors collected from advanced ccRCC patients enrolled in prospective clinical trials of treatment with PD-1 blockade (or mTOR inhibition as control arm) by whole-exome and RNA-sequencing, integrated with immunofluorescence analysis, to define the somatic alteration landscape of late-stage ccRCC and to uncover the immunogenomic determinants of therapeutic response. While conventional genomic markers (tumor mutation burden, neoantigen load) and degree of CD8+ T cell infiltration were not associated with clinical response, we discovered numerous chromosomal alterations in advanced ccRCC associated with response or resistance to PD-1 blockade. These advanced tumors were highly CD8+ T cell infiltrated, with only 22% and 5% with an immune desert and immune excluded phenotype, respectively. Our analysis revealed that CD8+ infiltrated tumors are depleted of favorable PBRM1 mutations and are enriched for unfavorable chromosomal losses of 9p21.3 when compared to non-infiltrated tumors. These data demonstrate how the interplay of somatic alterations and immunophenotypes impacts therapeutic efficacy.
- 53 samples
- DAC: EGAC00001001519
- Technology: Illumina HiSeq 2500
Requests for access the BMS accession numbers in EGA should be directed to the BMS FastTrack portal - https://fasttrack.bms.com/. This externally facing website serves as BMS’ request portal for all ISRs (both clinical and non-clinical), as well as for requests for data generated as a part of a BMS study. This portal is facilitated by BMS’ Clinical Trial Transparency organization.
Purpose Below you will find general notes and tips for when you are creating an ISR Request. General Notes and Tips • * [Asterisks] indicate a required field within the interface • You will not be able to move on to the next page if a required field is not completed • Periodically click Save (located at the bottom right corner on any form) in order to save your information. If you do not have all the information, which is necessary to submit your request, click Save and a draft will be available for you on your homepage when you are ready to return to the form. The forms do not auto-save. • FastTrack has a security time-out feature. After sixty (60) minutes of inactivity, you will be required to log back into the system. o If you are working on a record and leave it open while performing other tasks, it is recommend that you navigate to the bottom of the record and click Save to prevent you from losing data you have entered • You can return to any section of the form at any point by clicking the tabs at the top of the page or clicking Back in the lower left of the page We are committed to providing you with answers to your questions and concerns. Please contact us using the information below, and we will respond to your inquiry as quickly as possible. Technical Support Main Number: +1 844-439-5499 (US only) For Outside US, please see the “International BMS Help Desk Phone Number Guide” Main Email: hd-sci-apps@bms.com
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
Study ID | Study Title | Study Type |
---|---|---|
EGAS00001004291 | Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.